Cargando…
A state of the art review on the novel mediator asprosin in the metabolic syndrome
Metabolic syndrome is a complex and heterogeneous pathology characterized by a cluster of biochemical, clinical, and metabolic factors that came together in raising the risk of cardiovascular diseases, type 2 diabetes mellitus, and all-cause mortality. Some of these features are well defined in this...
Autores principales: | Luís, Carla, Fernandes, Rúben, Soares, Raquel, von Hafe, Pedro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732265/ https://www.ncbi.nlm.nih.gov/pubmed/33324783 http://dx.doi.org/10.1097/j.pbj.0000000000000108 |
Ejemplares similares
-
Asprosin: A Novel Player in Metabolic Diseases
por: Yuan, Mingyang, et al.
Publicado: (2020) -
Asprosin-neutralizing antibodies as a treatment for metabolic syndrome
por: Mishra, Ila, et al.
Publicado: (2021) -
Serum Asprosin Concentrations in Children with Prader–Willi Syndrome: Correlations with Metabolic Parameters
por: Alsaif, Maha, et al.
Publicado: (2022) -
High Serum Asprosin Levels Are Associated with Presence of Metabolic Syndrome
por: Hong, Tao, et al.
Publicado: (2021) -
The Effects of Asprosin on Exercise-Intervention in Metabolic Diseases
por: Liu, Lifei, et al.
Publicado: (2022)